For laboratory research use only. Not for human or veterinary use. Nothing on this page is medical advice, and no product is intended to diagnose, treat or prevent any condition.
IGF-1 LR3 vs IGF-1 DES: Key Differences for Research
IGF-1 LR3 and IGF-1 DES (des(1-3)IGF-1) are two engineered forms of insulin-like growth factor 1 (IGF-1), a 70-amino-acid protein that signals through the IGF-1 receptor (IGF-1R). Both were designed to answer the same laboratory problem: in serum and in many cell cultures, native IGF-1 is tightly bound by IGF-binding proteins (IGFBPs), which hide it from its receptor. Each analogue gets round this in a different way, and that difference decides which one suits a given experiment.
Structural differences
| Feature | Native IGF-1 | IGF-1 LR3 | IGF-1 DES |
|---|---|---|---|
| Length | 70 amino acids | 83 amino acids | 67 amino acids |
| Change | None | Arg at position 3 (in place of Glu) plus a 13-residue N-terminal extension | First three amino acids (Gly-Pro-Glu) removed |
| IGFBP binding | High | Greatly reduced | Greatly reduced |
| Main research use | Reference ligand | Long-lasting IGF-1R activation in culture and models | Potent, short-acting IGF-1R activation |
The LR3 analogues were described by Francis and colleagues, who showed that reducing IGFBP binding, rather than increasing receptor binding, was the main reason for their higher biological potency (Francis et al., J Mol Endocrinol 1992). Des(1-3)IGF-1 is a naturally occurring truncated form first found in bovine colostrum and brain; its properties are reviewed by Ballard et al., Int J Biochem Cell Biol 1996.
Why IGFBP binding matters in the lab
There are six main IGFBPs. In serum-containing media, and in cells that secrete their own IGFBPs, native IGF-1 can be largely sequestered. Ross and colleagues showed that IGFBPs blocked the biological activity of IGF-1 and IGF-2 but not des(1-3)IGF-1 (Ross et al., Biochem J 1989). Practically, this means that in an IGFBP-rich system, LR3 or DES will often produce a response at a lower concentration than native IGF-1. In serum-free systems with few IGFBPs, the differences shrink.
Receptor selectivity
Both analogues act mainly on IGF-1R. Like native IGF-1, they can bind the insulin receptor and IGF-1R/insulin receptor hybrids at high concentrations, so cross-reactivity should be checked in cell types that express a lot of insulin receptor. If a clean IGF-1R signal is essential, include an IGF-1R inhibitor or blocking antibody as a control, and run a concentration-response curve rather than a single concentration.
Half-life and timing in experimental systems
Because they escape IGFBPs, both analogues are cleared differently from native IGF-1 in animal models. LR3 is generally described as longer-lasting, while DES is more potent but shorter-lived. In cell culture, the more useful question is stability in the medium over the length of the experiment. For time-course work, sample at several points and consider replenishing the medium. Our peptide half-life guide explains the difference between half-life in a model and stability in a vial.
Typical research applications
- Cell culture supplements. LR3 is widely used in serum-free media for cell lines and in bioprocessing to support growth.
- Muscle cell biology. Both are used in myoblast and myotube models to study proliferation, differentiation and Akt/mTOR signalling.
- Metabolic signalling. Glucose uptake assays in muscle and fat cell lines, where insulin receptor cross-reactivity must be controlled.
- Local tissue models. DES is often chosen where a strong, short, local IGF-1R signal is wanted.
IGF-binding proteins: a short primer
| IGFBP | Notes relevant to lab work |
|---|---|
| IGFBP-1 | Regulated by insulin and nutrition; produced by liver and some cell lines |
| IGFBP-2 | Common in cell-conditioned media and cerebrospinal fluid |
| IGFBP-3 | Main serum carrier; forms a complex with the acid-labile subunit |
| IGFBP-4 | Generally inhibitory; cleaved by the protease PAPP-A |
| IGFBP-5 | Binds extracellular matrix; important in bone and muscle models |
| IGFBP-6 | Prefers IGF-2 over IGF-1 |
Knowing which IGFBPs your cells secrete helps predict how much difference an analogue will make. Measuring IGFBPs in conditioned medium by western ligand blot or ELISA is a simple way to characterise a new model before comparing IGF-1 forms.
Assay design checklist
- Decide whether your system contains IGFBPs (serum, conditioned media, cell type).
- Include native IGF-1 as a reference where possible.
- Run a full concentration-response curve for each analogue.
- Use an IGF-1R inhibitor control to confirm receptor specificity.
- Measure early signalling (phospho-IGF-1R, phospho-Akt, phospho-ERK) as well as later outcomes.
- Verify identity by mass spectrometry; LR3 and DES differ substantially in mass. See how to read HPLC and MS results.
IGF-1 signalling pathways in brief
When IGF-1, LR3 or DES binds IGF-1R, the receptor’s tyrosine kinase domains phosphorylate each other and then recruit adaptor proteins called IRS-1 and Shc. Two main pathways follow:
- PI3K/Akt/mTOR, linked to protein synthesis, cell survival and glucose uptake.
- Ras/MAPK (ERK), linked to proliferation and differentiation.
The balance between these pathways depends on cell type, receptor density and timing. A short, strong signal (more typical of DES) and a sustained signal (more typical of LR3) can push cells towards different outcomes, which is one practical reason to test both. Western blotting for phospho-Akt (Ser473) and phospho-ERK1/2 at early time points is a common way to confirm pathway activation before measuring slower outcomes such as protein synthesis or myotube size.
Which should you choose?
| If your experiment needs… | Consider |
|---|---|
| Sustained IGF-1R activation over a long culture period | IGF-1 LR3 |
| A short, potent IGF-1R signal | IGF-1 DES |
| A system with lots of IGFBPs | Either; both escape IGFBP binding |
| A physiological reference | Native IGF-1 alongside the analogue |
Reading the literature on LR3 and DES
Much of the published work on these analogues comes from Australian groups in the late 1980s and 1990s, who engineered them to study how IGF-binding proteins control IGF activity. Later work used them as tools in muscle, bone, neural and cancer cell biology. When reading a paper, check four things: which analogue was used (LR3, DES or native IGF-1), whether the medium contained serum, what concentration range was tested, and whether receptor specificity was confirmed with an inhibitor. Papers that skip these details are hard to compare.
It is also worth checking the reported outcome. A rise in cell number can reflect more proliferation, less cell death or both, and IGF-1R activates pathways linked to each. Measuring proliferation markers such as EdU or Ki-67 alongside apoptosis markers gives a clearer picture than a single viability assay.
Common mistakes when comparing LR3 and DES
- Comparing equal masses rather than equal molar amounts. LR3 is about 9.1 kDa and DES about 7.4 kDa, so the same number of micrograms gives a different number of molecules.
- Ignoring the medium. Results in serum-free medium may not hold when serum or conditioned medium is present.
- Using one time point. DES may show its strongest effect early, LR3 later.
- Not checking protein loss. Both can adsorb to plastic at low concentrations, which reduces the real amount reaching cells.
Storage and handling
Both are supplied as lyophilised powders. Store sealed vials cold and dry, reconstitute in a suitable dilute acid or buffer as specified, aliquot and avoid freeze-thaw cycles. Proteins of this size can stick to plastic, so low-protein-binding tubes and a carrier protein in working dilutions are common. See our IGF-1 LR3 storage and handling guide and reconstitution guide. For how IGF-1 LR3 compares with growth hormone, see IGF-1 LR3 vs HGH.
Frequently asked questions
What is the difference between IGF-1 LR3 and IGF-1 DES?
IGF-1 LR3 is an 83-amino-acid analogue with an arginine substitution and an N-terminal extension. IGF-1 DES lacks the first three amino acids of IGF-1. Both bind IGF-binding proteins far less than native IGF-1.
Why do IGF-1 analogues work better than native IGF-1 in some cell cultures?
Native IGF-1 is sequestered by IGF-binding proteins in serum and cell-conditioned media. LR3 and DES escape this binding, so more is available to the receptor.
Do IGF-1 LR3 and DES bind the insulin receptor?
They act mainly on the IGF-1 receptor but, like native IGF-1, can bind the insulin receptor at high concentrations. Controls are needed in insulin-receptor-rich cells.
How should IGF-1 LR3 be stored?
Store lyophilised powder cold and dry. After reconstitution, aliquot, keep cold and avoid repeated freeze-thaw cycles.
References
- Francis GL et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol 1992.
- Ballard FJ et al. Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I. Int J Biochem Cell Biol 1996.
- Ross M et al. Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1. Biochem J 1989.
